Retrovirus Epidemiology Donor Study (REDS) General Leukocyte/Plasma Repository (GLPR) - Catalog
Retrovirus Epidemiology Donor Study (REDS) General Leukocyte/Plasma Repository (GLPR)
HLB01890909a
REDS-GLPR
RD2
False
False
True
Coded
False
Epidemiology Study
Open BioLINCC Study
Adult
None
2009-10-01
2009-09-02
2021-11-04
1994-1995
DBDR
Transfusion Medicine
HIV-Related
non-COVID
60779
62310
Not Applicable (Specimens Only)
Not Applicable (Specimens Only)
No
Yes
Yes
Yes
Some biospecimens are restricted to research related to transfusion safety. Some biospecimens are not restricted.
Acquired Immunodeficiency Syndrome
Blood Donors
Blood Transfusion
HIV Infections
HIV-1
HIV-2
HTLV-I
HTLV-II
Retroviridae Infections
To provide researchers with an opportunity to conduct studies on a large representative sample of blood donors with linked demographic data and donation test results. Targeted investigations on particular subsets of the donor population are also feasible due to the availability of this linked data.
The Retrovirus Epidemiology Donor Study (REDS) has been conducted since 1989. One of the aims of this study is to establish blood specimen repositories for future testing. The General Leukocyte and Plasma Repository (GLPR) was established under this study.
The GLPR repository has already been used to investigate HHV-8 antibody prevalence in the US blood supply (1) and polymorphisms in chemokine receptor genes (2).
The GLPR was collected in 1994 and 1995 and consists of aliquots of plasma, and whole blood frozen, with or without DMSO, obtained from 147,915 blood donations.
Specimens for the GLPR repository were collected according to a statistical sampling plan, designed to obtain donations that are representative of all donor racial/ethnic groups. REDS blood centers that have contributed to the GLPR repository include: the American Red Cross (ARC) Greater Chesapeake and Potomac (Baltimore, MD; and Washington, DC), Southeastern Michigan (Detroit, MI), and Southern California (Los Angeles, CA) regions; the Blood Centers of the Pacific (BCP; San Francisco, CA); and the Oklahoma Blood Institute (Oklahoma City, OK).
Donor screening and testing was performed according to standard operating procedures and included tests for anti-HIV (types 1 and 2), anti-HCV, anti-HTLV, HBsAg and anti-HBc; serologic testing for syphilis and testing for ALT levels (3).
Pellett PE, et al. (2003) Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion 43(9):1260-1268. DOI: 10.1046/j.1537-2995.2003.00490.x
Mariani R, et al. (1999) CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. (Translated from eng) J Virol 73(3):2450-2459. DOI: 10.1128/JVI.73.3.2450-2459.1999
Zuck TF, et al. (1995) The Retrovirus Epidemiology Donor Study (REDS): rationale and methods. (Translated from eng) Transfusion 35(11):944-951. DOI: 10.1046/j.1537-2995.1995.351196110900.x
Plasma
Whole Blood
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process
-
Material Types
-
General Freeze/Thaw Status
-
Visits (Vials)
Last Modified: March 8, 2021, 4:28 p.m. -
Visits (Subjects)
03/08/2021
Plasma Total number of subjects Average volume (ml) per subject Subjects with 1 Draw 100,259 1.51 Subjects with 2 Draws 26,293 1.51 Subjects with 3 Draws 8,776 1.50 Subjects with 4-10 Draws 3,982 2.22 Subjects with 11+ Draws 85 3.48 Whole Blood Total number of subjects Average volume (ml) per subject Subjects with 1 Draw 104,159 0.99 Subjects with 2 Draws 27,484 1.00 Subjects with 3 Draws 9,264 1.02 Subjects with 4-10 Draws 4,163 1.58 Subjects with 11+ Draws 86 2.39
Last Modified: March 8, 2021, 4:28 p.m.